Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0519030 (Klebsiella)
 21,988 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Ampicillin-sensitive or -resistant Staphylococcus aureus and Klebsiella strains were cultured in various nutrient media as prototypes of the agents of sepsis isolated in bacteriological routine analysis. In each case, 2 ml of defibrinated human blood containing 100 and 1000 cells, 8 gamma and 80 gamma ampicillin/1 ml blood respectively were added to 50 ml of nutrient medium. The following media were used. 1. casein soya-bean meal peptone broth (Oxoid), 2. tryptose-phosphate medium (Oxoid), 3. dextrose broth (Oxoid), 4. brain-heart-dextrose medium (Oxoid), 5. brain-heart infusion, autoclaved (Difco), 6. brain-heart infusion, after sterile filtration (Difco), 7. vacutainer culture bottles (BD) prepared medium, 8. micrognost blood culture bottles (Biotest) prepared medium. While the sensitive staphylococcus strain exhibited a slower growth than the sensitive Klebsiella strain in all nutrient media, the growth rate of the two resistant variants was approximately the same for an initial count of 100 cells per ml of blood. Among the resistant staphylococci the higher initial count of the inoculum resulted in an improved growth. After addition of 8 gamma or 80 gamma ampicillin/1 ml blood the sensitive staphylococcus strain did not show any grwoth irrespective of the inoculated number of cells while the sensitive Klebsiella strain multiplied irrespective of the initial number of cells. After 24 hours the resistant staphylococci and Klebsiella strains of which 1000 cells each had been used for inoculation exhibited growth in almost all media used.
 ...
PMID:[Experimental studies to culture bacteria from blood specimen with an addition of ampicillin in various nutrient media (author's transl)]. 37 22

The in vitro activity of CP-99,219 was compared with that of ciprofloxacin and sparfloxacin against 814 clinical bacterial isolates using a microdilution method with brain-heart infusion broth. CP-99,219 was the most potent agent tested against methicillin-resistant, ciprofloxacin-susceptible staphylocci (minimum inhibitory concentration [MIC]90 < or = 0.25 microgram/ml). CP-99,219 was 32-fold and fourfold more potent than ciprofloxacin and sparfloxacin, respectively, against Streptococcus pneumoniae, including strains resistant to penicillin G and erythromycin (MIC90 < or = 0.25 microgram/ml). CP-99,219 was also the most potent agent tested against S. pyogenes and Enterococcus faecalis (MIC90 < or = 0.5 microgram/ml). The activity of CP-99,219 against Enterobacteriaceae was comparable to that of sparfloxacin, with 90% of Escherichia coli, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae, Citrobacter freundii, C. diversus, Helicobacter pylori, and K. oxytoca being inhibited by < or = 0.5 microgram/ml. Serratia marcescens, Morganella morganii, and Pseudomonas aeruginosa were less susceptible, with MIC90 values to CP-99,219 of 4, 2, and 2 micrograms/ml, respectively. The MIC90 for Bacteroides fragilis was 0.39 microgram/ml for CP-99,219 compared with 12.5 micrograms/ml for ciprofloxacin. CP-99,219 was highly bactericidal at 1 x to 4 x MIC against both Gram-positive and Gram-negative organisms; its activity was similar in nutrient, trypticase soy, and cation-supplemented Mueller-Hinton broths. The spectrum and potency observed with CP-99,219 warrant further testing with this novel quinolone.
 ...
PMID:In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial. 785 Oct 87